MXPA05004133A - Nuevos compuestos antitumorales. - Google Patents

Nuevos compuestos antitumorales.

Info

Publication number
MXPA05004133A
MXPA05004133A MXPA05004133A MXPA05004133A MXPA05004133A MX PA05004133 A MXPA05004133 A MX PA05004133A MX PA05004133 A MXPA05004133 A MX PA05004133A MX PA05004133 A MXPA05004133 A MX PA05004133A MX PA05004133 A MXPA05004133 A MX PA05004133A
Authority
MX
Mexico
Prior art keywords
kahalaide
methylhexanoic
compound
kahalalide
antitumoral
Prior art date
Application number
MXPA05004133A
Other languages
English (en)
Inventor
Del Carmen Cuevas Marcha Maria
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of MXPA05004133A publication Critical patent/MXPA05004133A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invencion se dirige a nuevos compuestos antitumorales kahalalide, en particular a analogos de kahalalide F, utiles como agentes antitumorales, antivirales, antifungicos y en el tratamiento de psoriasis.
MXPA05004133A 2002-10-18 2003-10-20 Nuevos compuestos antitumorales. MXPA05004133A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (1)

Publication Number Publication Date
MXPA05004133A true MXPA05004133A (es) 2005-10-05

Family

ID=32110555

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004133A MXPA05004133A (es) 2002-10-18 2003-10-20 Nuevos compuestos antitumorales.

Country Status (10)

Country Link
EP (1) EP1572726B1 (es)
JP (1) JP4430009B2 (es)
CN (2) CN101077885A (es)
BR (1) BR0315489A (es)
CA (1) CA2501089C (es)
ES (1) ES2357644T3 (es)
MX (1) MXPA05004133A (es)
NZ (1) NZ539093A (es)
WO (1) WO2004035613A2 (es)
ZA (1) ZA200502926B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
NZ584695A (en) * 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
DE102008005097B4 (de) * 2008-01-18 2011-04-07 Leibnitz-Institut für Meereswissenschaften Antitumoraler Cyclodepsipeptide, deren Herstellung und Verwendung
JP2011513370A (ja) * 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
CN106860870B (zh) 2010-11-12 2020-03-31 法马马有限公司 抗肿瘤生物碱的联合治疗
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
SK286421B6 (sk) * 2000-10-31 2008-09-05 Pharma Mar, S. A. Prostriedok kahalalid F, súprava, rekonštituovanýa zriedený roztok s obsahom tohto prostriedku a použitie
AU2002334203C1 (en) * 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
CA2501089A1 (en) 2004-04-29
CN101077885A (zh) 2007-11-28
NZ539093A (en) 2007-10-26
ES2357644T3 (es) 2011-04-28
WO2004035613A2 (en) 2004-04-29
ZA200502926B (en) 2006-02-22
CA2501089C (en) 2012-07-17
JP2006517195A (ja) 2006-07-20
BR0315489A (pt) 2005-08-23
EP1572726A2 (en) 2005-09-14
CN1705677A (zh) 2005-12-07
CN100591691C (zh) 2010-02-24
WO2004035613A3 (en) 2004-07-29
EP1572726B1 (en) 2010-12-08
JP4430009B2 (ja) 2010-03-10

Similar Documents

Publication Publication Date Title
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
MXPA02011288A (es) Tioacetamidas substituidas.
MXPA04003796A (es) Tioacetamidas sustituidas.
GB0225474D0 (en) Therapeutic agents
SI1663242T1 (sl) 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
MY126527A (en) Novel dihydropyrimidines
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
GB0111186D0 (en) Novel compounds
MXPA03006562A (es) Composcion tipo azeotropo de 1,2-dicloro-3,3,3-trifluoropropeno y fluoruro de hidrogeno.
MXPA05004133A (es) Nuevos compuestos antitumorales.
GB0216001D0 (en) Process and composition
EP1667685A4 (en) INHIBITORS OF QUINAZOLINE-BASED POTASSIUM CANAL
MXPA02011039A (es) Combinaciones de productos activos fungicidas.
EP1667976A4 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
GB0326633D0 (en) Therapeutic agents
HK1082261A1 (en) 4-methylhexanoic kahalalide f compound
ATE372330T1 (de) N-sulfonylurea-apoptosis-förderer
AU2001247241A1 (en) Biologically active analogs of discodermolide
HK1074435A1 (en) Compounds that stimulate glucose utilization and methods of use
MXPA05012605A (es) Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
TW200607493A (en) Potassium channel inhibitors
IL142295A0 (en) Use of acylcarnitines as antitumour agents

Legal Events

Date Code Title Description
FG Grant or registration